BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

527 related articles for article (PubMed ID: 28011243)

  • 41. Sirolimus- versus paclitaxel-eluting stents for the treatment of cardiac allograft vasculopathy.
    Lee MS; Tarantini G; Xhaxho J; Yang T; Ehdaie A; Bhatia R; Favaretto E; Tobis J
    JACC Cardiovasc Interv; 2010 Apr; 3(4):378-82. PubMed ID: 20398863
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Sirolimus-eluting versus paclitaxel-eluting stents in diabetic and non-diabetic patients within sirolimus-eluting stent restenosis: results from the ISAR-DESIRE 2 trial.
    Kufner S; Byrne RA; de Waha A; Schulz S; Joner M; Laugwitz KL; Kastrati A;
    Cardiovasc Revasc Med; 2014 Mar; 15(2):69-75. PubMed ID: 24684757
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical and angiographic outcomes with an everolimus-eluting stent in large coronary arteries: the SPIRIT III 4.0 mm registry.
    Gordon PC; Applegate RJ; Hermiller JB; Weinsier SB; Doostzadeh J; Cao S; Sudhir K; Lansky AJ; Stone GW
    Catheter Cardiovasc Interv; 2010 Feb; 75(2):179-86. PubMed ID: 19877267
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Long-term safety and efficacy with paclitaxel-eluting stents: 5-year final results of the TAXUS IV clinical trial (TAXUS IV-SR: Treatment of De Novo Coronary Disease Using a Single Paclitaxel-Eluting Stent).
    Ellis SG; Stone GW; Cox DA; Hermiller J; O'Shaughnessy C; Mann T; Turco M; Caputo R; Bergin PJ; Bowman TS; Baim DS;
    JACC Cardiovasc Interv; 2009 Dec; 2(12):1248-59. PubMed ID: 20129552
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Impact of vessel size on outcome after implantation of sirolimus-eluting and paclitaxel-eluting stents: a subgroup analysis of the SIRTAX trial.
    Togni M; Eber S; Widmer J; Billinger M; Wenaweser P; Cook S; Vogel R; Seiler C; Eberli FR; Maier W; Corti R; Roffi M; Lüscher TF; Garachemani A; Hess OM; Wandel S; Meier B; Jüni P; Windecker S
    J Am Coll Cardiol; 2007 Sep; 50(12):1123-31. PubMed ID: 17868802
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The Valentines Trial: results of the first one week worldwide multicentre enrolment trial, evaluating the real world usage of the second generation DIOR paclitaxel drug-eluting balloon for in-stent restenosis treatment.
    Stella PR; Belkacemi A; Waksman R; Stahnke S; Torguson R; von Strandmann RP; Agostoni P; Sangiorgi G; Silber S;
    EuroIntervention; 2011 Oct; 7(6):705-10. PubMed ID: 21959672
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Primary percutaneous coronary intervention by drug-eluting balloon angioplasty: the nonrandomized fourth arm of the DEB-AMI (drug-eluting balloon in ST-segment elevation myocardial infarction) trial.
    Nijhoff F; Agostoni P; Belkacemi A; Nathoe HM; Voskuil M; Samim M; Doevendans PA; Stella PR
    Catheter Cardiovasc Interv; 2015 Oct; 86 Suppl 1():S34-44. PubMed ID: 26119971
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison of three-year clinical outcomes between sirolimus-versus paclitaxel-eluting stents in diabetic patients: prospective randomized multicenter trial.
    Hong SJ; Kim MH; Cha KS; Park HS; Chae SC; Hur SH; Gwon HC; Bae JH; Lim DS
    Catheter Cardiovasc Interv; 2010 Dec; 76(7):924-33. PubMed ID: 20815045
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Paclitaxel-eluting balloon versus everolimus-eluting stent in patients with diabetes mellitus and in-stent restenosis: Insights from the randomized DARE trial.
    Claessen BE; Henriques JPS; Vendrik J; Boerlage-van Dijk K; van der Schaaf RJ; Meuwissen M; van Royen N; Gosselink ATM; van Wely MH; Dirkali A; Arkenbout EK; Piek JJ; Baan J
    Catheter Cardiovasc Interv; 2019 Feb; 93(2):216-221. PubMed ID: 30232824
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Catheter-based delivery of fluid paclitaxel for prevention of restenosis in native coronary artery lesions after stent implantation.
    Herdeg C; Göhring-Frischholz K; Haase KK; Geisler T; Zürn C; Hartmann U; Wöhrle J; Nusser T; Dippon J; May AE; Gawaz M
    Circ Cardiovasc Interv; 2009 Aug; 2(4):294-301. PubMed ID: 20031731
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A clinical and angiographic study of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with multivessel coronary artery disease: the EXECUTIVE trial (EXecutive RCT: evaluating XIENCE V in a multi vessel disease).
    Ribichini F; Romano M; Rosiello R; La Vecchia L; Cabianca E; Caramanno G; Milazzo D; Loschiavo P; Rigattieri S; Musarò S; Pironi B; Fiscella A; Amico F; Indolfi C; Spaccarotella C; Bartorelli A; Trabattoni D; Della Rovere F; Rolandi A; Beqaraj F; Belli R; Sangiorgio P; Villani R; Berni A; Sheiban I; Lopera Quijada MJ; Cappi B; Ribaldi L; Vassanelli C;
    JACC Cardiovasc Interv; 2013 Oct; 6(10):1012-22. PubMed ID: 24055444
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The REMEDEE trial: a randomized comparison of a combination sirolimus-eluting endothelial progenitor cell capture stent with a paclitaxel-eluting stent.
    Haude M; Lee SW; Worthley SG; Silber S; Verheye S; Erbs S; Rosli MA; Botelho R; Meredith I; Sim KH; Stella PR; Tan HC; Whitbourn R; Thambar S; Abizaid A; Koh TH; Den Heijer P; Parise H; Cristea E; Maehara A; Mehran R
    JACC Cardiovasc Interv; 2013 Apr; 6(4):334-43. PubMed ID: 23523459
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A prospective, multicenter, randomized trial of paclitaxel-coated balloon versus paclitaxel-eluting stent for the treatment of drug-eluting stent in-stent restenosis: results from the PEPCAD China ISR trial.
    Xu B; Gao R; Wang J; Yang Y; Chen S; Liu B; Chen F; Li Z; Han Y; Fu G; Zhao Y; Ge J;
    JACC Cardiovasc Interv; 2014 Feb; 7(2):204-211. PubMed ID: 24556098
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Five-year clinical outcomes of a polymer-free sirolimus-eluting stent versus a permanent polymer paclitaxel-eluting stent: final results of the intracoronary stenting and angiographic restenosis - test equivalence between two drug-eluting stents (ISAR-TEST) trial.
    King L; Byrne RA; Mehilli J; Schömig A; Kastrati A; Pache J
    Catheter Cardiovasc Interv; 2013 Jan; 81(1):E23-8. PubMed ID: 22431239
    [TBL] [Abstract][Full Text] [Related]  

  • 55. In-stent restenosis: the gold standard has changed.
    Chin K
    EuroIntervention; 2011 May; 7 Suppl K():K43-6. PubMed ID: 22027726
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A 10-month angiographic and 4-year clinical outcome of everolimus-eluting versus sirolimus-eluting coronary stents in patients with diabetes mellitus (the DiabeDES IV randomized angiography trial).
    Maeng M; Baranauskas A; Christiansen EH; Kaltoft A; Holm NR; Krusell LR; Ravkilde J; Tilsted HH; Thayssen P; Jensen LO
    Catheter Cardiovasc Interv; 2015 Dec; 86(7):1161-7. PubMed ID: 25640050
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Gender-based evaluation of the XIENCE V everolimus-eluting coronary stent system: clinical and angiographic results from the SPIRIT III randomized trial.
    Lansky AJ; Ng VG; Mutlu H; Cristea E; Guiran JB; Midei M; Newman W; Sanz M; Sood P; Doostzadeh J; Su X; White R; Cao S; Sudhir K; Stone GW
    Catheter Cardiovasc Interv; 2009 Nov; 74(5):719-27. PubMed ID: 19530147
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Late-term clinical outcomes with zotarolimus- and sirolimus-eluting stents. 5-year follow-up of the ENDEAVOR III (A Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions).
    Kandzari DE; Mauri L; Popma JJ; Turco MA; Gurbel PA; Fitzgerald PJ; Leon MB
    JACC Cardiovasc Interv; 2011 May; 4(5):543-50. PubMed ID: 21596327
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Stent coverage and neointimal proliferation in bare metal stents postdilated with a Paclitaxel-eluting balloon versus everolimus-eluting stents: prospective randomized study using optical coherence tomography at 6-month follow-up.
    Poerner TC; Otto S; Gassdorf J; Nitsche K; Janiak F; Scheller B; Goebel B; Jung C; Figulla HR
    Circ Cardiovasc Interv; 2014 Dec; 7(6):760-7. PubMed ID: 25371536
    [TBL] [Abstract][Full Text] [Related]  

  • 60. 5-year results of a randomized comparison of XIENCE V everolimus-eluting and TAXUS paclitaxel-eluting stents: final results from the SPIRIT III trial (clinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions).
    Gada H; Kirtane AJ; Newman W; Sanz M; Hermiller JB; Mahaffey KW; Cutlip DE; Sudhir K; Hou L; Koo K; Stone GW
    JACC Cardiovasc Interv; 2013 Dec; 6(12):1263-6. PubMed ID: 24239202
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.